High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

@article{Madan2012HighdoseMA,
  title={High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.},
  author={Sumit Madan and S Kumar and Angela Dispenzieri and Martha Q Lacy and Suzanne R. Hayman and Francis K Buadi and David Dingli and S. Vincent Rajkumar and William J Hogan and Nelson Leung and Martha Grogan and Morie A Gertz},
  journal={Blood},
  year={2012},
  volume={119 5},
  pages={
          1117-22
        }
}
High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement. We studied 187 patients with cardiac involvement with AL who underwent HDM between 1996 and 2008. The median age was 57 years and the median time from diagnosis to HDM was 3.6 months. Half of the patients received reduced-dose melphalan (100-160 mg/m(2)). The median overall survival (OS… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 31 CITATIONS

Diagnostik und Therapie der kardialen Amyloidose

  • Der Kardiologe
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Advances in Treatment of Cardiac Amyloid

  • Current Treatment Options in Cardiovascular Medicine
  • 2018
VIEW 1 EXCERPT
CITES METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Changes in serum - free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloido

S Kumar, A Dispenzieri, JA Katzmann
  • Am J Hematol
  • 2011

rum immunoglobulin free light - chain measurement in primary amyloidosis : prognostic value and correlations with clinical features

MA Gertz, MQ Lacy, A Dispenzieri
  • Blood
  • 2010